David Hough
About David Hough
David Hough is the Head of Clinical Development known for leading the first FDA-approved therapeutic in the hallucinogen classes and previously served as Vice President at Janssen.
David Hough's Role as Head of Clinical Development
David Hough currently serves as the Head of Clinical Development. In this capacity, Hough led the development of the first and only FDA-approved therapeutic within the hallucinogen classes. His role encompasses overseeing comprehensive aspects, ensuring all medical, scientific, manufacturing, quality, preclinical, and commercial facets are strategically managed to meet regulatory standards and patient needs.
David Hough's Tenure at Janssen
David Hough spent 17 years at Janssen (a Johnson & Johnson company), where he held various leadership roles, ultimately rising to the position of Vice President. During his tenure, he contributed significantly to the development and approval of several key treatments. His extensive experience and leadership within the organization were pivotal in advancing medicinal therapeutics in several domains.
Leadership in SPRAVATO Program Development
David Hough was the compound development team leader for SPRAVATO (esketamine). Under his leadership, the development program successfully navigated through two severe mood disorder indications. He was responsible for all facets of the program, including medical, scientific, manufacturing, quality, preclinical, and commercial aspects, playing a crucial role in bringing this therapy to the market.
Contributions to Schizophrenia Therapeutics
David Hough played a pivotal role in the development of key schizophrenia treatments during his time at Janssen. He served as the schizophrenia disease area leader and the development team leader for paliperidone. His efforts were instrumental in the development of oral INVEGA (paliperidone) and the 1-month and 3-month formulations of INVEGA SUSTENNA/XEPLION (paliperidone palmitate), which have become important therapeutic options for patients.